Novartis AG has received FDA approval for its Tekturna HCT drug for treating high blood pressure. The drug, which is a combination of the hypertension drug Tekturna (aliskiren) and diuretic (water pill) hydrochlorothiazide (HCT), was found to “offer greater blood pressure reductions that either component alone,” the company said. Possible side-effects include dizziness, diarrhea, cough and allergy. Novartis expects Tektruna HCT to hit the market in early February.

See the full release here